Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

Open access
Moayyedi, Paul, Eikelboom, John W., Bosch, Jackie, Connolly, Stuart J., Dyal, Leanne, Shestakovska, Olga, Leong, Darryl, Anand, Sonia S., Störk, Stefan, Branch, Kelly R.H., Bhatt, Deepak L., Verhamme, Peter B., O’Donnell, Martin, Maggioni, Aldo P., Lonn, Eva M., Piegas, Leopoldo S., Ertl, Georg, Keltai, Matyas, Cook Bruns, Nancy, Muehlhofer, Eva, Dagenais, Gilles R., Kim, Jae-Hyung, Hori, Masatsugu, Steg, P. Gabriel, Hart, Robert G., Diaz, Rafael, Alings, Marco, Widimsky, Petr, Avezum, Alvaro, Probstfield, Jeffrey, Zhu, Jun, Liang, Yan, Lopez-Jaramillo, Patricio, Kakkar, Ajay, Parkhomenko, Alexander N., Ryden, Lars, Pogosova, Nana, Dans, Antonio, Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek, Vinereanu, Dragos, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Metsarinne, Kaj, Fox, Keith A.A., Yusuf, Salim·2019·Gastroenterology

Abstract

BACKGROUND & AIMS Antiplatelet and anticoagulants are associated with increased upper gastrointestinal bleeding. We evaluated whether proton pump inhibitor therapy could reduce this risk. METHODS We performed a 3x2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and peripheral artery disease. Participants were randomly assigned to groups given pantoprazole 40 mg daily or placebo, as well as rivaroxaban 2.5 mg twice daily with aspirin 100 mg once daily, rivaroxaban 5 mg twice daily, or aspirin 100 mg alone. The primary outcome was time to first upper gastrointestinal event, defined as a composite of overt bleeding, upper gastrointestinal bleeding from a gastroduodenal lesion or of unknown origin, occult bleeding, symptomatic gastroduodenal ulcer or ≥5 erosions, upper gastrointestinal obstruction, or perforation. RESULTS There was no significant difference in upper gastrointestinal events between the pantoprazole group (102/8791 events) and the placebo group (116/8807 events) (hazard ratio [HR], 0.88; 95% CI, 0.67-1.15). Pantoprazole significantly reduced bleeding of gastroduodenal lesions (HR, 0.52; 95% CI, 0.28-0.94; P=.03); this reduction was greater when we used a post-hoc definition of bleeding gastroduodenal lesion (HR, 0.45; 95% CI, 0.27-0.74) although the number needed to treat still was high (982; 95% CI, 609-2528). CONCLUSIONS In a randomized placebo-controlled trial, we found that routine use of proton pump inhibitors in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease does not reduce upper gastrointestinal events but may reduce bleeding from gastroduodenal lesions. Clinicaltrials.gov no: NCT01776424.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.04.041

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 158

Metadata

Authors
Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Störk, S., Branch, K. R. H., Bhatt, D. L., Verhamme, P. B., O’Donnell, M., Maggioni, A. P., Lonn, E. M., Piegas, L. S., Ertl, G., Keltai, M., Cook Bruns, N., Muehlhofer, E., Dagenais, G. R., Kim, J.-H., Hori, M., Steg, P. G., Hart, R. G., Diaz, R., Alings, M., Widimsky, P., Avezum, A., Probstfield, J., Zhu, J., Liang, Y., Lopez-Jaramillo, P., Kakkar, A., Parkhomenko, A. N., Ryden, L., Pogosova, N., Dans, A., Lanas, F., Commerford, P. J., Torp-Pedersen, C., Guzik, T., Vinereanu, D., Tonkin, A. M., Lewis, B. S., Felix, C., Yusoff, K., Metsarinne, K., Fox, K. A. A., & Yusuf, S.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-08
Volume
157
Issue
2
Pages
403-412.e5
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2942638642
Cited by
158
References
4
FWCI
15.81
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1053/j.gastro.2019.04.041
The paper
Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Störk, S., Branch, K. R. H., Bhatt, D. L., Verhamme, P. B., O’Donnell, M., Maggioni, A. P., Lonn, E. M., Piegas, L. S., Ertl, G., Keltai, M., Cook Bruns, N., . . . Yusuf, S. (2019). Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.04.041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.